Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class

Dyne Therapeutics lead asset z-rostudirsen faces regulatory and confirmatory risks, with FDA approval likely. Find out why ...

So many election surveys. So few voters willing to pick up the phone.

The missed call log in Dr. Eric Bai’s iPhone has a sea of phone numbers with unfamiliar area codes. Some of them are likely from pollsters wanting to ask him about the upcoming Rhode Island primary ...
Magnolia Reporter

Magnolia Three-Day Weather/Sky Report: It’s still hot

Dangerous early-September heat will continue across Magnolia through Tuesday, while skywatchers will have opportunities to ...